In this issue:
Final analysis of survival in the FIRST trial in MM
Induction VCD in MM
Inpatient vs. outpatient autologous SCT for MM
Predicting newly diagnosed MM outcomes
High-cutoff vs conventional haemodialysis in myeloma cast nephropathy
Daratumumab + VMP for untreated myeloma
Long-term MGUS follow-up
Ixazomib increases PFS in high-risk relapsed/refractory MM
Venetoclax for relapsed/ refractory t(11;14) MM
Please login below to download this issue (PDF)